Trevi Therapeutics, Inc. (TRVI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$12.61-2.55%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Trevi Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.142
Annual ending 2026-12-31
Revenue	—	1.1M
EPS	—	-0.481
Annual ending 2027-12-31
Revenue	—	3.47M
EPS	—	-0.615

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage cash runway with existing cash and offering proceeds	It manages cash runway with recent offering proceeds.	Intact	Cash runway falls below 12 months before next funding event	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management completed a $162 million net proceeds stock offering in April 2026, increasing cash and marketable securities to $318.9 million by Q2 2026, extending cash runway into 2030. This financial position supports funding clinical development and aligns with management's stated cash runway goals, indicating delivering progress. Delivery assessment Oct 24, 2026
Reduce losses and improve EPS trajectory	A supporting condition in Trevi Therapeutics, Inc.'s published investment case. The stated target is EPS loss narrows from -0.47 in 2026 to better levels by 2027.	Intact	EPS loss worsens beyond -0.56 in 2027	Diluted EPS: $-0.11 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -0.47 in 2026 to better levels by 2027. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.11 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 1ac06070-2190-486c-b1e1-40310c7e037e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain FDA alignment on IPF-related chronic cough development plan	Trevi plans two pivotal Phase 3 trials for IPF-related chronic cough.	Intact	Loss of FDA alignment or negative regulatory feedback by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management completed an End-of-Phase 2 meeting with FDA in Q1 2026 achieving alignment on IPF-related chronic cough development plans and plans further FDA meetings for non-IPF ILD-related chronic cough. This shows delivering regulatory engagement consistent with stated priorities. Delivery assessment Oct 24, 2026
Conduct two pivotal Phase 3 trials for IPF-related chronic cough	Trevi plans two pivotal Phase 3 trials for IPF-related chronic cough.	Intact	Failure to initiate or significant delays in Phase 3 trials by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management initiated the Phase 3 OCEAN-1 trial in Q2 2026 and plans to start the OCEAN-2 trial in Q3 2026, with topline results expected in 2027 and 2028. This aligns with management's stated execution plans and shows delivering progress on clinical development. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.61

$-0.56 → $-0.61 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.56	$0	10 / 10
2026-07-25	$-0.56	$0	10 / 10
2026-07-26	$-0.56	$0	10 / 10
2026-07-27	$-0.56	$0	10 / 10
2026-07-28	$-0.56	$0	10 / 10
2026-07-29	$-0.59	$3,466,667	8 / 6
2026-07-30	$-0.56	$0	10 / 10
2026-07-31	$-0.56	$0	10 / 10
2026-08-01	$-0.59	$3,466,667	8 / 6
2026-08-02	$-0.56	$0	10 / 10
2026-08-03	$-0.56	$0	10 / 10
2026-08-04	$-0.56	$0	10 / 10
2026-08-05	$-0.59	$3,466,667	8 / 6
2026-08-06	$-0.56	$0	10 / 10
2026-08-08	$-0.59	$3,466,667	8 / 6
2026-08-09	$-0.56	$0	10 / 10
2026-08-10	$-0.59	$3,466,667	8 / 6
2026-08-12	$-0.57	$0	10 / 10
2026-08-13	$-0.59	$3,466,667	8 / 6
2026-08-14	$-0.59	$3,466,667	8 / 6
2026-08-15	$-0.59	$3,466,667	8 / 6
2026-08-16	$-0.59	$3,466,667	8 / 6
2026-08-17	$-0.59	$3,466,667	8 / 6
2026-08-18	$-0.59	$3,466,667	8 / 6
2026-08-19	$-0.59	$3,466,667	8 / 6
2026-08-20	$-0.61	$3,466,667	8 / 6
2026-08-21	$-0.61	$3,466,667	8 / 6
2026-08-22	$-0.61	$3,466,667	8 / 6
2026-08-23	$-0.61	$3,466,667	8 / 6
2026-08-24	$-0.61	$3,466,667	8 / 6
2026-08-25	$-0.61	$3,466,667	8 / 6
2026-08-26	$-0.61	$3,466,667	8 / 6
2026-08-27	$-0.61	$3,466,667	8 / 6
2026-08-28	$-0.61	$3,466,667	8 / 6
2026-08-29	$-0.61	$3,466,667	8 / 6
2026-08-30	$-0.61	$3,466,667	8 / 6
2026-08-31	$-0.61	$3,466,667	8 / 6
2026-09-01	$-0.61	$3,466,667	8 / 6
2026-09-02	$-0.61	$3,466,667	8 / 6
2026-09-03	$-0.61	$3,466,667	8 / 6
2026-09-04	$-0.61	$3,466,667	8 / 6
2026-09-05	$-0.61	$3,466,667	8 / 6
2026-09-06	$-0.61	$3,466,667	8 / 6
2026-09-07	$-0.61	$3,466,667	8 / 6
2026-09-08	$-0.61	$3,466,667	8 / 6
2026-09-09	$-0.61	$3,466,667	8 / 6
2026-09-10	$-0.61	$3,466,667	8 / 6
2026-09-11	$-0.61	$3,466,667	8 / 6
2026-09-12	$-0.61	$3,466,667	8 / 6
2026-09-13	$-0.61	$3,466,667	8 / 6
2026-09-14	$-0.61	$3,466,667	8 / 6
2026-09-15	$-0.61	$3,466,667	8 / 6
2026-09-16	$-0.61	$3,466,667	8 / 6
2026-09-17	$-0.61	$3,466,667	8 / 6
2026-09-18	$-0.61	$3,466,667	8 / 6
2026-09-19	$-0.61	$3,466,667	8 / 6
2026-09-20	$-0.61	$3,466,667	8 / 6
2026-09-21	$-0.61	$3,466,667	8 / 6
2026-09-22	$-0.61	$3,466,667	8 / 6
2026-09-23	$-0.61	$3,466,667	8 / 6
2026-09-24	$-0.61	$3,466,667	8 / 6
2026-09-25	$-0.61	$3,466,667	8 / 6
2026-09-26	$-0.61	$3,466,667	8 / 6
2026-09-27	$-0.61	$3,466,667	8 / 6
2026-09-28	$-0.61	$3,466,667	8 / 6
2026-09-29	$-0.61	$3,466,667	8 / 6
2026-09-30	$-0.61	$3,466,667	8 / 6
2026-10-01	$-0.61	$3,466,667	8 / 6
2026-10-02	$-0.61	$3,466,667	8 / 6
2026-10-03	$-0.61	$3,466,667	8 / 6
2026-10-04	$-0.61	$3,466,667	8 / 6
2026-10-05	$-0.61	$3,466,667	8 / 6
2026-10-06	$-0.61	$3,466,667	8 / 6
2026-10-07	$-0.61	$3,466,667	8 / 6
2026-10-08	$-0.61	$3,466,667	8 / 6
2026-10-09	$-0.61	$3,466,667	8 / 6
2026-10-10	$-0.61	$3,466,667	8 / 6
2026-10-11	$-0.61	$3,466,667	8 / 6
2026-10-12	$-0.61	$3,466,667	8 / 6
2026-10-13	$-0.61	$3,466,667	8 / 6
2026-10-14	$-0.61	$3,466,667	8 / 6
2026-10-15	$-0.61	$3,466,667	8 / 6
2026-10-16	$-0.61	$3,466,667	8 / 6
2026-10-17	$-0.61	$3,466,667	8 / 6
2026-10-18	$-0.61	$3,466,667	8 / 6
2026-10-19	$-0.61	$3,466,667	8 / 6
2026-10-20	$-0.61	$3,466,667	8 / 6
2026-10-21	$-0.61	$3,466,667	8 / 6
2026-10-22	$-0.61	$3,466,667	8 / 6
2026-10-23	$-0.61	$3,466,667	8 / 6
2026-10-24	$-0.61	$3,466,667	8 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	11	0	0
2026-06-01	11	0	0
2026-07-01	11	0	0
2026-08-01	11	0	0
2026-09-01	11	0	0
2026-10-01	11	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage cash runway with existing cash and offering proceedsDirect metric needs a verified mapping
Reduce losses and improve EPS trajectoryDiluted EPS: $-0.11 per share
Maintain FDA alignment on IPF-related chronic cough development planDirect metric needs a verified mapping
Conduct two pivotal Phase 3 trials for IPF-related chronic coughDirect metric needs a verified mapping

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-39.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Trevi Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder: the evidence describes the company as loss-making, with weak recent financial performance and elevated risk. The long-term thesis is in a watch state, with low overall confidence, despite progress on clinical and funding priorities.

What's priced into Trevi Therapeutics, Inc.

The snapshot gives no valuation multiple or direct measure of market expectations, so whether TRVI is cheap, fair, or expensive versus peers cannot be assessed. It reports low valuation fragility, meaning no flagged signs that the setup is especially vulnerable to a change in expectations, but that does not establish what growth the market assumes.

What the fundamentals likely do

Near term, the record is mixed: two earnings misses in April and May 2026 were followed by an in-line report in August, while a next-call guidance cut remains a stated risk. Across the multi-year thesis, the company has started the OCEAN-1 Phase 3 trial, plans to start OCEAN-2, and has cash runway stated to extend into 2030 after an offering; trial outcomes are expected in 2027 and 2028. The risk remains elevated, and recent financial performance is well below its industry cohort.

What Trevi Therapeutics, Inc. hinges on

The multi-year case hinges on execution of the Phase 3 program and continued regulatory alignment on chronic cough development. Near term, a guidance cut or further weakening in jobs data could add pressure, while stronger results and guidance from healthcare sector peers could support sector momentum.